According to a study in Cancer Medicine, there is a lack of patient-reported evidence on the symptom burden and impact on daily activities of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT). Researchers conducted a survey and reported that respondents identified high cGVHD symptom burden and felt their symptoms significantly interfered with physical functioning and activities of daily living (ADL). ...
Advertisement
Latest News
Researchers found bronchiolitis obliterans syndrome was less frequent in HCT with HID donors compared with MSD and MUDs.
Researchers found sVCAM-1 levels were higher pre- and post-HCT in patients who developed severe aGVHD.
Extracellular vesicles at engraftment in hematopoietic cell transplantation may be a feasible biomarker for acute GVHD.
A study looks at previous adjuvant therapy treatments to determine the future of adjuvant therapy use for localized RCC.
Patients with steroid-refractory acute graft-versus-host disease who received ECP had better survival than those who did not.
Investigators found greater risk for severe acute graft-versus-host disease in omitting the day 11 dose of mini-methotrexate.
Expert Interviews
Conference Highlights
The GVHD rate was around 5% in patients receiving Orca-T, a high-precision, regulatory T-cell-engineered donor product.
GVHD occurred more with a fludarabine-based flipped conditioning regimen than with a cyclophosphamide-based flipped regimen.
The presence and number of clonal plasma cells in an autograft are predictive of posttransplant outcomes in multiple myeloma.
Noncryopreserved and cryopreserved peripheral blood stem cells (PBSC) lead to similar patient outcomes after transplant.
Most patients did not have extensive chronic GVHD after a mismatched transplant with this pretransplant conditioning regimen.
Patients transplanted with omidubicel had better quality of life than patients transplanted with umbilical cord blood.
